Pacmilimab by CytomX Therapeutics for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas.

Source link
#Pacmilimab #CytomX #Therapeutics #Gastroesophageal #Junction #Carcinomas #Likelihood #Approval